{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:32:17Z","timestamp":1785583937608,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,9]]},"DOI":"10.7759\/cureus.83773","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:50:45Z","timestamp":1746784245000},"source":"Crossref","is-referenced-by-count":3,"title":["Calcinosis Cutis With Selective Fibroblast Growth Factor Receptor Inhibitors: A Case Report and Review of Literature"],"prefix":"10.7759","author":[{"given":"Bipin","family":"Ghimire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhairya","family":"Gor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12071002","article-title":"Role of basic fibroblast growth factor in cancer: biological activity, targeted therapies, and prognostic value","volume":"12","author":"Ardizzone A","year":"2023","unstructured":"Ardizzone A, Bova V, Casili G, et al.. Role of basic fibroblast growth factor in cancer: biological activity, targeted therapies, and prognostic value. Cells. 2023, 12:10.3390\/cells12071002","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang P","year":"2024","unstructured":"Zhang P, Yue L, Leng Q, Chang C, Gan C, Ye T, Cao D. Targeting FGFR for cancer therapy. J Hematol Oncol. 2024, 17:39. 10.1186\/s13045-024-01558-1","journal-title":"J Hematol Oncol"},{"key":"ref3","unstructured":"WITHDRAWN. FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma. (2024). Accessed: October 2, 2024: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-fda-grants-accelerated-approval-infigratinib...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture ME","year":"2021","unstructured":"Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou-Alfa G. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist. 2021, 26:e316-26. 10.1002\/onco.13552","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah V","year":"2023","unstructured":"Subbiah V, Verstovsek S. Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med. 2023, 4:101204. 10.1016\/j.xcrm.2023.101204","journal-title":"Cell Rep Med"},{"key":"ref6","article-title":"Calcinosis cutis","author":"Le C","year":"2024","unstructured":"Le C, Bedocs PM. Calcinosis cutis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024. 15:"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00530108","article-title":"Calciphylaxis from nonuremic causes: a systematic review","volume":"3","author":"Nigwekar SU","year":"2008","unstructured":"Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008, 3:1139-43. 10.2215\/CJN.00530108","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21478","article-title":"Calciphylaxis cutis associated with fibroblast growth factor receptor (FGFR) inhibitor therapy: a new challenge","volume":"14","author":"Griffith P","year":"2022","unstructured":"Griffith P, Jedrych J, Sunshine J, Laheru DA, Yarchoan M. Calciphylaxis cutis associated with fibroblast growth factor receptor (FGFR) inhibitor therapy: a new challenge. Cureus. 2022, 14:e21478. 10.7759\/cureus.21478","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13319","article-title":"Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor","volume":"45","author":"Arudra K","year":"2018","unstructured":"Arudra K, Patel R, Tetzlaff MT, et al.. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018, 45:786-90. 10.1111\/cup.13319","journal-title":"J Cutan Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-139","article-title":"Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib-a case report","volume":"15","author":"Chandana SR","year":"2024","unstructured":"Chandana SR, Frisch A, Mendoza S, Sinniah RS, Crysler O, Banga R, Perkins DE. Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib-a case report. J Gastrointest Oncol. 2024, 15:478-84. 10.21037\/jgo-23-139","journal-title":"J Gastrointest Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2024.103304","article-title":"Pemigatinib-associated calcinosis cutis: First case of complete regression with continued phosphate chelator therapy","volume":"151","author":"Chantreau PL","year":"2024","unstructured":"Chantreau PL, Lebidre E, Tallegas M, Dujardin F, Samimi M, Kervarrec T. Pemigatinib-associated calcinosis cutis: First case of complete regression with continued phosphate chelator therapy. Ann Dermatol Venereol. 2024, 151:103304. 10.1016\/j.annder.2024.103304","journal-title":"Ann Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2022.07.001","article-title":"Hyperphosphatemic tumoral calcinosis with pemigatinib use","volume":"8","author":"Puar A","year":"2022","unstructured":"Puar A, Donegan D, Helft P, Kuhar M, Webster J, Rao M, Econs M. Hyperphosphatemic tumoral calcinosis with pemigatinib use. AACE Clin Case Rep. 2022, 8:217-20. 10.1016\/j.aace.2022.07.001","journal-title":"AACE Clin Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.10.040","article-title":"Fibroblast growth factor receptor inhibitor therapy induced calcinosis cutis treated with sodium thiosulfate","volume":"31","author":"Qian J","year":"2023","unstructured":"Qian J, Li JN, Rose EK, et al.. Fibroblast growth factor receptor inhibitor therapy induced calcinosis cutis treated with sodium thiosulfate. JAAD Case Rep. 2023, 31:128-32. 10.1016\/j.jdcr.2022.10.040","journal-title":"JAAD Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.4076","article-title":"Fibroblast growth factor receptor inhibitors and nonuremic calciphylaxis","volume":"157","author":"Hirner J","year":"2021","unstructured":"Hirner J, Cleary JM, Sheets A, Murphy G, LeBoeuf N. Fibroblast growth factor receptor inhibitors and nonuremic calciphylaxis. JAMA Dermatol. 2021, 157:119-21. 10.1001\/jamadermatol.2020.4076","journal-title":"JAMA Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.11.022","article-title":"Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib","volume":"7","author":"Macklis P","year":"2021","unstructured":"Macklis P, Chung C, Kaffenberger B. Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib. JAAD Case Rep. 2021, 7:125-7. 10.1016\/j.jdcr.2020.11.022","journal-title":"JAAD Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4070","article-title":"Metastatic calcinosis cutis associated with a selective FGFR inhibitor","volume":"155","author":"Carr DR","year":"2019","unstructured":"Carr DR, Pootrakul L, Chen HZ, Chung CG. Metastatic calcinosis cutis associated with a selective FGFR inhibitor. JAMA Dermatol. 2019, 155:122-3. 10.1001\/jamadermatol.2018.4070","journal-title":"JAMA Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3438","article-title":"Metastatic calcinosis cutis secondary to selective fibroblast growth factor receptor inhibitor: rapid and complete regression after blood phosphate normalization and drug withdrawal","volume":"100","author":"Lopez-Castillo D","year":"2020","unstructured":"Lopez-Castillo D, March-Rodriguez A, Rodriguez-Vida A, Pujol RM, Segura S. Metastatic calcinosis cutis secondary to selective fibroblast growth factor receptor inhibitor: rapid and complete regression after blood phosphate normalization and drug withdrawal. Acta Derm Venereol. 2020, 100:adv00079. 10.2340\/00015555-3438","journal-title":"Acta Derm Venereol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2646","article-title":"Safety profile and adverse event management for futibatinib, an irreversible FGFR1-4 inhibitor: pooled safety analysis of 469 patients","volume":"30","author":"Meric-Bernstam F","year":"2024","unstructured":"Meric-Bernstam F, Hollebecque A, Furuse J, et al.. Safety profile and adverse event management for futibatinib, an irreversible FGFR1-4 inhibitor: pooled safety analysis of 469 patients. Clin Cancer Res. 2024, 30:1466-77. 10.1158\/1078-0432.CCR-23-2646","journal-title":"Clin Cancer Res"},{"key":"ref19","article-title":"Calciphylaxis","author":"Westphal SG","year":"2024","unstructured":"Westphal SG, Plumb T. Calciphylaxis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/365958-calcinosis-cutis-with-selective-fibroblast-growth-factor-receptor-inhibitors-a-case-report-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:50:46Z","timestamp":1746784246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/365958-calcinosis-cutis-with-selective-fibroblast-growth-factor-receptor-inhibitors-a-case-report-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.83773","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}